Published in Eur Heart J on April 10, 2007
The new oral anticoagulants. Neth Heart J (2010) 1.06
New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. Int J Nanomedicine (2011) 0.83
Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals. Neth Heart J (2010) 0.82
Attitudes and preferences on the use of mobile health technology and health games for self-management: interviews with older adults on anticoagulation therapy. JMIR Mhealth Uhealth (2014) 0.82
Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well? Curr Cardiol Rev (2010) 0.80
Risk of bleeding associated with interventional musculoskeletal radiology procedures. A comprehensive review of the literature. Skeletal Radiol (2014) 0.76
Documentation of various approaches and outcomes in patients on warfarin undergoing dental procedures: a review article. Am J Cardiovasc Dis (2016) 0.75
Monitoring of anticoagulant therapy in heart disease: considerations for the current assays. J Tehran Heart Cent (2010) 0.75
Also the very elderly benefit from warfarin in atrial fibrillation. Neth Heart J (2007) 0.75
Perioperative evaluation of cardiac surgical risk: particularities in the emergency surgery - from the guidelines to the clinical practice. J Med Life (2013) 0.75
Zn2+ mediates high affinity binding of heparin to the αC domain of fibrinogen. J Biol Chem (2013) 0.75
Management of pregnant women with artificial heart valves: inconsistency in ESC publications. Eur Heart J (2007) 0.75
Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nat Rev Cardiol (2010) 0.75
Delayed airway obstruction after internal jugular venous catheterization in a patient with anticoagulant therapy. Case Rep Anesthesiol (2011) 0.75
Feasibility Study of a Mobile Health Intervention for Older Adults on Oral Anticoagulation Therapy. Gerontol Geriatr Med (2016) 0.75
[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts]. Wien Klin Wochenschr (2013) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Universal definition of myocardial infarction. Circulation (2007) 11.69
Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64
Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med (2009) 10.60
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med (2005) 7.80
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med (2012) 4.37
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Clinical trial registration--looking back and moving ahead. N Engl J Med (2007) 4.07
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet (2014) 4.05
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med (2002) 3.91
Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA (2011) 3.90
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
Analyses of cancer data from three ezetimibe trials. N Engl J Med (2008) 3.44
A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg (2014) 3.43
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA (2007) 3.28
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Concern Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J (2009) 3.14
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J (2006) 3.10
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet (2006) 3.01
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 2.98
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J (2012) 2.94
Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J (2005) 2.94
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol (2002) 2.87
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet (2002) 2.85
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81
Pre-hospital triage for primary angioplasty: direct referral to the intervention center versus interhospital transport. JACC Cardiovasc Interv (2010) 2.77